Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TScan Therapeutics, Inc. - Common Stock (NQ:TCRX)

0.2240 +0.0138 (+6.57%)
Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TScan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Unusual volume stocks in Tuesday's session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Here are the top movers in Wednesday's session. ↗
Via Chartmill
Which stocks are gapping on Wednesday? ↗
Via Chartmill
News headline image
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
Actively enrolling patients across the US with anticipated topline data readout mid-2028 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
From Cellares
Via Business Wire
News headline image
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Discover the top movers in Monday's pre-market session. ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Which stocks are moving on Wednesday? ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in Upcoming Investor Conferences
From TScan Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.